The US FDA has broadened its investigation into AstraZeneca COVID-19 vaccine candidate

The US Food and Drug Administration iw widening the enquiry, seeking more data from clinical trials

  • FDA seeking raw safety data from clinical trials of similar vaccines developed by same scientists
  • The FDA does not necessarily indicate a safety problem associated with any of those vaccines

The market has been acting constructively on positive coronavirus vaccine stories. This is not a positive (in the short term at least) so should impact the opposite on risk.

Reuters have a report with further detail here:
  • AstraZeneca’s large, late-stage U.S. trial has remained on hold since Sept. 6, after a study participant in Britain fell ill 
  • The widened scope of the FDA probe raises the likelihood of additional delays for what has been one of the most advanced COVID-19 vaccine candidates in development. The requested data was expected to arrive this week, after which the FDA would need time to analyze it, two of the sources said.
I covered the main points on this in an earlier post here: The US FDA has broadened its investigation into AstraZeneca COVID-19 vaccine candidate